Rare diseases
Investigational molecules
Locations
379 conditions with trials, the busiest first
1 291 trials across Europe, recruiting first
Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)
BelgiumPumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
AustriaEIK1001, Pembrolizumab, and Chemotherapy for Stage 4 Non-Small Cell Lung Cancer in Patients with Stage 4 Non-Small Cell Lung Cancer
AustriaErdosteine in Patients With COPD
ItalyZongertinib with cisplatin or carboplatin and pemetrexed, with or without pembrolizumab, for patients with locally advanced or metastatic non-squamous non-small cell lung cancer with HER2 mutations
FranceBMS-986525 Alone and with Nivolumab in Patients with Relapsed or Refractory Small Cell Lung Cancer
ItalyPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
AustriaDermatophagoides farinae, Dermatophagoides pteronyssinus, and Lepidoglyphus destructor Immunotherapy for Allergic Rhinitis and Rhinoconjunctivitis in Patients With or Without Mild Asthma
SpainGB-0895 for Severe Uncontrolled Asthma in Adults and Adolescents
BulgariaA Study of BI 764532, Atezolizumab, Carboplatin, and Etoposide in Patients With Extensive-Stage Small Cell Lung Cancer
AustriaTotal-Body PET with [18F]Flutemetamol in Patients with Post-COVID Syndrome (Long COVID)
The NetherlandsA study to evaluate the safety and effectiveness of rilvegostomig, ramucirumab, and a drug combination in adults with advanced or metastatic non-small cell lung cancer
FranceThe therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
